Compare Stocks → Strange new buyer driving up gold (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EPZMNASDAQ:INCRNASDAQ:KALVNASDAQ:RLYBOTCMKTS:SEOVF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPZMEpizyme$1.47$1.47$0.41▼$5.80$247.44M-0.413.23 million shs7,960 shsINCRInterCure$2.53-2.3%$2.15$0.99▼$2.92$115.29M1.7382,626 shs6,573 shsKALVKalVista Pharmaceuticals$11.50$12.78$7.21▼$16.88$485.19M0.88743,893 shs215,920 shsRLYBRallybio$1.73+3.6%$1.81$1.23▼$9.14$65.41M-1.641.37 million shs256,172 shsSEOVFSernova$0.33$0.42$0.29▼$0.83$99.97M1.1619,754 shs29,167 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPZMEpizyme0.00%0.00%0.00%0.00%0.00%INCRInterCure+9.75%+6.58%+29.50%+82.39%+17.73%KALVKalVista Pharmaceuticals-1.29%-4.96%-2.87%-7.33%+39.90%RLYBRallybio-5.11%-43.96%+4.37%+15.97%-63.22%SEOVFSernova+0.33%-13.29%-21.77%-27.28%-46.85%Strange new buyer driving up gold (Ad)One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."But there's a much better move you can make to get in front of these big moves today.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEPZMEpizymeN/AN/AN/AN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/AN/AN/AN/AKALVKalVista Pharmaceuticals3.9629 of 5 stars3.51.00.04.62.82.50.6RLYBRallybio2.3754 of 5 stars3.41.00.00.03.71.71.3SEOVFSernovaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEPZMEpizymeN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AKALVKalVista Pharmaceuticals3.00Buy$26.33128.99% UpsideRLYBRallybio2.83Moderate Buy$12.20605.20% UpsideSEOVFSernova2.00Hold$1.50355.24% UpsideCurrent Analyst RatingsLatest KALV, EPZM, RLYB, SEOVF, and INCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024RLYBRallybioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$8.004/11/2024KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.004/11/2024RLYBRallybioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$13.00 ➝ $11.004/4/2024SEOVFSernovaRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform$1.503/13/2024RLYBRallybioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $9.003/13/2024RLYBRallybioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$8.002/14/2024KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $24.002/13/2024KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $35.002/7/2024RLYBRallybioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$16.00 ➝ $8.002/7/2024RLYBRallybioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$14.00 ➝ $13.002/7/2024RLYBRallybioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $12.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEPZMEpizyme$37.43M6.61N/AN/A($0.54) per share-2.72INCRInterCure$115.83M1.00$0.42 per share5.99$3.64 per share0.70KALVKalVista PharmaceuticalsN/AN/AN/AN/A$4.71 per shareN/ARLYBRallybioN/AN/AN/AN/A$2.81 per shareN/ASEOVFSernovaN/AN/AN/AN/A$0.03 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEPZMEpizyme-$251.12M-$1.72N/AN/AN/A-391.90%-2,459.33%-69.74%N/AINCRInterCure$13.36M$0.1319.46∞N/AN/AN/AN/A5/20/2024 (Estimated)KALVKalVista Pharmaceuticals-$92.91M-$3.15N/AN/AN/AN/A-86.06%-72.65%7/5/2024 (Estimated)RLYBRallybio-$74.56M-$1.84N/AN/AN/AN/A-56.90%-53.38%5/14/2024 (Estimated)SEOVFSernova-$28.91M-$0.09N/A∞N/AN/A-226.64%-145.26%6/12/2024 (Estimated)Latest KALV, EPZM, RLYB, SEOVF, and INCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q1 2024SEOVFSernovaN/A-$0.02-$0.02-$0.02N/AN/A3/12/2024Q4 2023RLYBRallybio-$0.44-$0.50-$0.06-$0.50N/AN/A3/11/2024Q3 2024KALVKalVista Pharmaceuticals-$0.75-$0.84-$0.09-$0.84N/AN/A1/29/2024Q4 2023SEOVFSernovaN/A-$0.03-$0.03-$0.03N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEPZMEpizymeN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/ARLYBRallybioN/AN/AN/AN/AN/ASEOVFSernovaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEPZMEpizymeN/A5.355.19INCRInterCureN/AN/AN/AKALVKalVista PharmaceuticalsN/A5.445.44RLYBRallybioN/A12.3912.39SEOVFSernova0.141.201.20OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEPZMEpizyme76.45%INCRInterCure8.34%KALVKalVista PharmaceuticalsN/ARLYBRallybio90.34%SEOVFSernovaN/AInsider OwnershipCompanyInsider OwnershipEPZMEpizyme23.40%INCRInterCure0.24%KALVKalVista Pharmaceuticals12.30%RLYBRallybio5.80%SEOVFSernovaN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEPZMEpizyme250168.33 million128.97 millionOptionableINCRInterCure37045.57 million45.46 millionOptionableKALVKalVista Pharmaceuticals11842.19 million37.00 millionOptionableRLYBRallybio4337.81 million35.62 millionNot OptionableSEOVFSernovaN/A303.41 millionN/ANot OptionableKALV, EPZM, RLYB, SEOVF, and INCR HeadlinesSourceHeadlineSernova Names Nicholas Rossettos Interim CFOmarketwatch.com - March 11 at 1:39 PMSernova reports anticipated 2024 milestonesmsn.com - January 29 at 10:40 AMSernova gets FDA orphan drug, rare pediatric designations for hemophilia Amsn.com - November 27 at 8:15 PMClosing Bell: Sernova Corp flat on Tuesday (SVA)theglobeandmail.com - November 14 at 9:04 PMSernova Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congressfinance.yahoo.com - October 30 at 7:35 AMSernova Presents Compelling New Data on the Cell Pouch System™ as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual Meetingfinance.yahoo.com - September 29 at 1:00 PMSernova Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Devicefinance.yahoo.com - September 7 at 10:11 AMSernova Appoints Cynthia Pussinen as Chief Executivemarketwatch.com - September 5 at 4:32 PMSernova appoints CEOseekingalpha.com - September 5 at 4:32 PMSernova reports positive interim data for Cell Pouch Systemmassdevice.com - June 26 at 6:49 PMSernova (SVA) Receives a Buy from H.C. Wainwrightmarkets.businessinsider.com - June 26 at 8:00 AMSernova to Present Updated Interim Phase 1/2 Clinical Data on Cell Pouch System™ During Oral Presentation at American Diabetes Association 83rd Scientific Sessionsfinance.yahoo.com - June 22 at 6:01 PMSernova is significantly undervalued, says Echeloncantechletter.com - June 16 at 11:36 PMSernova to Participate in Upcoming Truist Securities Cell Therapy Symposiumfinance.yahoo.com - June 16 at 1:35 PMEchelon Wealth Partners Remains a Buy on Sernova (SVA)markets.businessinsider.com - June 15 at 3:50 PMSernova Announces Executive Alignment and Appoints New Board Chairfinance.yahoo.com - May 31 at 8:58 AMClosing Bell: Sernova Corp flat on Monday (SVA)theglobeandmail.com - May 8 at 9:43 PMSernova Corp. Announces Voting Results of the 2023 Annual General Meeting of Shareholdersthenewswire.com - April 28 at 3:38 PMClosing Bell: Sernova Corp flat on Thursday (SVA)theglobeandmail.com - April 28 at 10:37 AMConcerned Shareholders of Sernova Corp. Wish to Thank All Shareholdersfinance.yahoo.com - April 25 at 6:02 PMSernova Reminds Shareholders to Vote FOR the Eight Management Director Nominees Using ONLY the WHITE Management Proxythenewswire.com - April 21 at 12:40 PMProxy adviser backs diabetes device developer Sernova in fight against activist investorsmedtechdive.com - April 17 at 3:33 PMSernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the Medfinance.yahoo.com - April 10 at 8:20 AMSernova defends record after investors attack ‘sluggish’ progress of regenerative medicine implantmedtechdive.com - April 7 at 3:12 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEpizymeNASDAQ:EPZMEpizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.InterCureNASDAQ:INCRInterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.KalVista PharmaceuticalsNASDAQ:KALVKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.RallybioNASDAQ:RLYBRallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.SernovaOTCMKTS:SEOVFSernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.